The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Unresectable Chemorefractory Liver Metastases: Radioembolization with90Y Microspheres—Safety, Efficacy, and Survival
Abstract
PURPOSE: To prospectively evaluate the safety, efficacy, and survival of patients with chemorefractory liver metastases who have been treated with yttrium 90 ((90)Y) glass microspheres. MATERIALS AND METHODS: Institutional review boards from two institutions approved the HIPAA-compliant study; all patients provided informed consent. One hundred thirty-seven patients underwent 225 administrations of (90)Y microspheres by using intraarterial infusion. Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung, cholangiocarcinoma, melanoma, renal, esophageal, ovary, adenocarcinoma of unknown primary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal, and parotid. Patients underwent evaluation of baseline and follow-up liver function and tumor markers and computed tomographic or magnetic resonance imaging. Patients were observed for survival from first treatment. Median survival (in days) and corresponding 95% confidence intervals were computed by using the Kaplan-Meier method. The log-rank statistic was used for statistical significance testing of survival distributions between various subgroups of patients. RESULTS: There were 66 men and 71 women. All patients were treated on an outpatient basis. Median age was 61 years. The mean number of treatments was 1.6. The median activity and dose infused were 1.83 GBq and 112.8 Gy, respectively. Clinical toxicities included fatigue (56%), vague abdominal pain (26%), and nausea (23%). At follow-up imaging, according to World Health Organization criteria, there was a 42.8% response rate (2.1% complete response, 40.7% partial response). There was a biologic tumor response (any decrease in tumor size) of 87%. Overall median survival was 300 days. One-year survival was 47.8%, and 2-year survival was 30.9%. Median survival was 457 days for patients with colorectal tumors, 776 days for those with neuroendocrine tumors, and 207 days for those with noncolorectal, nonneuroendocrine tumors. CONCLUSION: (90)Y hepatic treatments are well tolerated with acceptable toxicities; tumor response and median survival are promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Cited by
Salem, R., Gilbertsen, M., Butt, Z., Memon, K., Vouche, M., Hickey, R., Baker, T., Abecassis, M. M., Atassi, R., Riaz, A., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.028 · Cited by 258
Self-citation
Metadata
- Authors
- Sato, K. T., Lewandowski, R. J., Mulcahy, M. F., Atassi, B., Ryu, R. K., Gates, V. L., Nemcek, A. A., Barakat, O., Benson, A., Mandal, R., Talamonti, M., Wong, C.-Y. O., Miller, F. H., Newman, S. B., Shaw, J. M., Thurston, K. G., Omary, R. A., & Salem, R.
- Venue
- Radiology
- Published
- 2008-05
- Volume
- 247
- Issue
- 2
- Pages
- 507-515
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2153307137
- Cited by
- 226
- References
- 2
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unresectable Chemorefractory Liver Metastases: Radioembolization with90Y Microspheres—Safety, Efficacy, and Survival. https://app.cochat.ai/papers/10.1148/radiol.2472062029
- The paper
- Sato, K. T., Lewandowski, R. J., Mulcahy, M. F., Atassi, B., Ryu, R. K., Gates, V. L., Nemcek, A. A., Barakat, O., Benson, A., Mandal, R., Talamonti, M., Wong, C.-Y. O., Miller, F. H., Newman, S. B., Shaw, J. M., Thurston, K. G., Omary, R. A., & Salem, R. (2008). Unresectable Chemorefractory Liver Metastases: Radioembolization with90Y Microspheres—Safety, Efficacy, and Survival. Radiology. https://doi.org/10.1148/radiol.2472062029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.